LSE:SAR (Sareum Holdings plc)
About SAR
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders.
Sareum Holdings plc (LSE: SAR) Latest News
Investing Articles
Can the AIM-listed Sareum stock price keep rising?
Investing Articles
Should I invest in penny stock Sareum (LSE:SAR)?
Investing Articles
The SAR share price has jumped 1,000%. Should I buy now?
Investing Articles
UK investors are buying Sareum Holdings. Should I?
Investing Articles
What’s going on with the Sareum Holdings share price?
Investing Articles
Is this penny stock a buy for me after its 14% jump today?
Investing Articles
Can the Sareum share price keep climbing?
Investing Articles
Should You Buy Blinkx Plc, Electrocomponents plc And Sareum Holdings Plc On Today’s News?
Investing Articles
Why Traders Are Moving Goodwin plc And Sareum Holdings Plc Today
❮2